SCHEMBL6847487

SCHEMBL6847487

FC(F)(F)c1ccc(-c2ccc3c(ccn3-c3cccnc3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.43
CYP11B1 P15538 3/20 0.43
S1PR1 P21453 1/20 0.42
KCNH2 Q12809 2/20 0.42
NPC1 O15118 1/20 0.42
DGAT1 O75907 1/20 0.42
KIF11 P52732 1/20 0.41
HTR6 P50406 2/20 0.41
HTR2B P41595 1/20 0.41
GSK3B P49841 2/20 0.40
NPY5R Q15761 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
MCHR1 Q99705 1/20 0.39
ERBB2 P04626 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
LCK P06239 1/20 0.38
KIT P10721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6658095 0.90 NR3C1 (0.50) CYP11B2CYP11B1KCNH2DGAT1KIF11
SCHEMBL6846000 0.90 CDC7 (0.43) CYP11B2CYP11B1S1PR1KCNH2NPC1
SCHEMBL6846113 0.88 CYP11B2 (0.48) CYP11B2CYP11B1HTR6CYP3A4
SCHEMBL6840644 0.87 KIF11 (0.52) CYP11B2CYP11B1KCNH2KIF11CYP3A4
SCHEMBL6656090 0.85 CYP11B2 (0.50) CYP11B2CYP11B1KCNH2CYP3A4NR3C1
SCHEMBL6655119 0.85 CYP11B2 (0.51) CYP11B2CYP11B1HTR6CYP3A4NR3C1
SCHEMBL6846125 0.84 CYP11B2 (0.59) CYP11B2CYP11B1CYP3A4
SCHEMBL16538914 0.83 CYP11B2 (0.49) CYP11B2CYP11B1HTR6CYP3A4
SCHEMBL22515748 0.83 CYP11B2 (0.49) CYP11B2CYP11B1HTR6CYP3A4NR3C1
SCHEMBL6662535 0.83 CYP19A1 (0.51) CYP11B2CYP11B1KCNH2NPC1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 CYP11B2 53/4885CYP11B1 30/4885S1PR1 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.